New drug JNJ-95437446 enters early human trials for advanced cancers

NCT ID NCT07107230

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 26 times

Summary

This early-stage study is testing a new drug called JNJ-95437446 in about 380 adults with advanced solid tumors, including colorectal, lung, and head and neck cancers that have spread or cannot be removed. The main goals are to find safe doses and check for side effects. Researchers will also watch for signs that the drug shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro
RECRUITING

Madrid, 28050, Spain
Hosp Univ Vall D Hebron
RECRUITING

Barcelona, 8035, Spain
Hosp. Univ. 12 de Octubre
RECRUITING

Madrid, 28041, Spain
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

COLORECTAL NEOPLASMS